Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04582669 · ClinicalTrials.gov registry record · Phase 4
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
A Phase 4 study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT04582669 is a Phase 4 study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT04582669, a Phase 4 study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
Currently, there is limited evidence showing increased resolution of HS flares with higher doses of intralesional triamcinolone (ILTAC) as well as a difference in side effect profile between the doses. The goal of this study is to determine the efficacy of treating HS flares with ILTAC-10, ILTAC-20 and ILTAC-40 and to investigate the side effect profile for each dose.
Interventions
- DRUG Placebo
- DRUG Intralesional Triamcinolone 10 mg/mL
- DRUG Intralesional Triamcinolone 20 mg/mL
- DRUG Intralesional Triamcinolone 40 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2022-10-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04582669
The ClinicalTrials.gov registry entry for NCT04582669 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04582669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04582669 about?
NCT04582669 is a clinical study titled "Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa". Currently, there is limited evidence showing increased resolution of HS flares with higher doses of intralesional triamcinolone (ILTAC) as well as a difference in side effect profile between the doses. The goal of this study is to determine the efficacy of treating HS flares with ILTAC-10, ILTAC-20 ...
What is the current status of trial NCT04582669?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2022-01-24. Estimated completion is 2022-10-12.
What interventions are being tested in trial NCT04582669?
The interventions under investigation include: Placebo (DRUG), Intralesional Triamcinolone 10 mg/mL (DRUG), Intralesional Triamcinolone 20 mg/mL (DRUG), Intralesional Triamcinolone 40 mg/mL (DRUG).
Who is sponsoring clinical trial NCT04582669?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.